Structural and metabolic changes in Atp7b-/- mouse liver and potential for new interventions in Wilson's disease

Annals of the New York Academy of Sciences

Volumn 1315, Issue 1, 2014, Pages 37-44

  Huster, Dominik ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

ATP7B; Copper toxicity; Inherited disease; Liver; Metabolism

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMITOTIC AGENT; ANTIOXIDANT; CARDIOLIPIN; CHELATING AGENT; CHOLESTEROL; COPPER; CYTOCHROME C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; MEMBRANE LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; WILSON DISEASE PROTEIN;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHRONIC INFLAMMATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON MICROSCOPY; FATTY LIVER; GENE EXPRESSION; GENE THERAPY; GENOTYPE PHENOTYPE CORRELATION; HEPATOCYTE TRANSPLANTATION; HISTOPATHOLOGY; HUMAN VERSUS ANIMAL COMPARISON; LIPID METABOLISM; LIVER CELL; LIVER INJURY; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER REGENERATION; LIVER STRUCTURE; LIVER TOXICITY; MALIGNANT TRANSFORMATION; MITOCHONDRIAL MEMBRANE; MOUSE; MOUSE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; REDOX STRESS; WILSON DISEASE;

ATP7B; COPPER TOXICITY; INHERITED DISEASE; LIVER; METABOLISM;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CATION TRANSPORT PROTEINS; CELL CYCLE; CHOLESTEROL; COPPER; DISEASE MODELS, ANIMAL; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER; MICE; MICE, KNOCKOUT; MITOCHONDRIA, LIVER;

EID: 84900023905     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12337     Document Type: Article

References (51)

1. Tapiero H., D. M. Townsend & K. D. Tew. 2003. Trace elements in human physiology and pathology. Copper. Biomed. Pharmacother. 57: 386-398.
2. Schumann, K. et al. 2002. Hohenheim consensus workshop: copper. Eur. J. Clin. Nutr. 56: 469-483.
3. Tsivkovskii, R., T. Purnat & S. Lutsenko. 2004. Copper-transporting ATPases: key regulators of intracellular copper concentration. In Handbook of ATPases. M. Futai, Y. Wada & J. Kaplan, Eds.: 99-158. Weinheim: Wiley-VCH Verlag GmbH & Co.
4. Huster, D. 2010. Wilson disease. Best Pract. Res. Clin. Gastroenterol. 24: 531-539.
5. Ferenci, P. 2005. Wilson's Disease. Clin Gastroenterol. Hepatol. 3: 726-733.
6. Gitlin, J. D. 2003. Wilson disease. Gastroenterology 125: 1868-1877.
7. Riordan, S. M. & R. Williams. 2001. The Wilson's disease gene and phenotypic diversity. J. Hepatol. 34: 165-171.
8. Lorincz, M. T. 2010. Neurologic Wilson's disease. Ann. N. Y. Acad. Sci. 1184: 173-187.
9. Ferenci, P. 2004. Pathophysiology and clinical features of Wilson disease. Metab. Brain Dis. 19: 229-239.
10. Bull, P. C. et al. 1993. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 5: 327-337.
11. Tanzi, R. E. et al. 1993. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. 5: 344-350.
12. Yamaguchi, Y., M. E. Heiny & J. D. Gitlin. 1993. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem. Biophys. Res. Commun. 197: 271-277.
13. Yoshida, M. C. et al. 1987. New mutation causing hereditary hepatitis in the laboratory rat. J. Hered. 78: 361-365.
14. Mori, M. et al. 1994. The LEC rat: a model for human hepatitis, liver cancer, and much more. Am. J. Pathol. 144: 200-204.
15. Rauch, H. 1983. Toxic milk, a new mutation affecting cooper metabolism in the mouse. J. Hered. 74: 141-144.
16. Coronado, V., M. Nanji & D. W. Cox. 2001. The Jackson toxic milk mouse as a model for copper loading. Mamm. Genome. 12: 793-795.
17. Buiakova, O. I. et al. 1999. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum. Mol. Genet. 8: 1665-1671.
18. Huster, D. et al. 2006. Consequences of copper accumulation in the livers of the atp7b-/- (Wilson disease gene) knockout mice. Am. J. Pathol. 168: 423-434.
19. Langner, C. & H. Denk. 2004. Wilson disease. Virchows Arch. 445: 111-118.
20. Ponomarev, A. B., E. N. Kosminkova & S. Generalova. 1994. [Diffuse cholangiocarcinoma in the context of multilobular liver cirrhosis as a manifestation of Wilson-Konovalov disease]. Arkh. Patol. 56: 74-77.
21. Walshe, J. M. et al. 2003. Abdominal malignancies in patients with Wilson's disease. QJM 96: 657-662.
22. Polio, J. et al. 1989. Hepatocellular carcinoma in Wilson's disease. Case report and review of the literature. J. Clin. Gastroenterol. 11: 220-224.
23. Wright, L. M. et al. 2009. Hepatocyte GP73 expression in Wilson disease. J. Hepatol. 51: 557-564.
24. Delangle, P. & E. Mintz. Chelation therapy in Wilson's disease: from D-penicillamine to the design of selective bioinspired intracellular Cu(I) chelators. Dalton Trans. 41: 6359-6370.
25. Llanos, R. M. & J. F. Mercer. 2002. The molecular basis of copper homeostasis copper-related disorders. DNA Cell. Biol. 21: 259-270.
26. Valko, M., H. Morris & M. T. Cronin. 2005. Metals, toxicity and oxidative stress. Curr. Med. Chem. 12: 1161-208.
27. Nair, J. et al. 1998. Lipid peroxidation-induced etheno-DNA adducts in the liver of patients with the genetic metal storage disorders Wilson's disease and primary hemochromatosis. Cancer Epidemiol. Biomarkers Prev. 7: 435-40.
28. Carmichael, P. L. et al. 1995. Detection of bulky DNA lesions in the liver of patients with Wilson's disease and primary haemochromatosis. Mutat. Res. 326: 235-243.
29. Sauer, S. W. et al. 2011. Severe dysfunction of respiratory chain and cholesterol metabolism in Atp7b(-/-) mice as a model for Wilson disease. Biochim. Biophys. Acta. 1812: 1607-1615.
30. Zischka, H. et al. 2011. Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease. J. Clin. Invest. 121: 1508-1518.
31. Sternlieb, I. 1980. Copper and the liver. Gastroenterology. 78: 1615-1628.
32. Sternlieb, I. et al. 1995. An array of mitochondrial alterations in the hepatocytes of Long-Evans Cinnamon rats. Hepatology. 22: 1782-1787.
33. Roberts, E. A., B. H. Robinson & S. Yang. 2008. Mitochondrial structure and function in the untreated Jackson toxic milk (tx-j) mouse, a model for Wilson disease. Mol. Genet. Metab. 93: 54-65.
34. Biempica, L. et al. 1988. Morphologic and chemical studies on a murine mutation (toxic milk mice) resulting in hepatic copper toxicosis. Lab. Invest. 59: 500-508.
35. Kroemer, G. & J. C. Reed. 2000. Mitochondrial control of cell death. Nat. Med. 6: 513-519.
36. Petrosillo, G., F. M. Ruggiero & G. Paradies. 2003. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. Faseb. J. 17: 2202-2208.
37. Malhi, H., M. E. Guicciardi & G. J. Gores. Hepatocyte death: a clear and present danger. Physiol. Rev. 90: 1165-1194.
38. Ardail, D. et al. 1990. Mitochondrial contact sites. Lipid composition and dynamics. J. Biol. Chem. 265: 18797-18802.
39. Shadyro, O. et al. 2004. Formation of phosphatidic acid, ceramide, and diglyceride on radiolysis of lipids: identification by MALDI-TOF mass spectrometry. Free Radic. Biol. Med. 36: 1612-1624.
40. Yurkova, I. L. et al. 2008. Formation of phosphatidic acid in stressed mitochondria. Arch. Biochem. Biophys. 480: 17-26.
41. Yurkova, I. L. et al. 2011. Fragmentation of mitochondrial cardiolipin by copper ions in the Atp7b-/- mouse model of Wilson's disease. Chem. Phys. Lipids. 164: 393-400.
42. Huster, D. et al. 2007. High copper selectively alters lipid metabolism and cell cycle machinery in the mouse model of Wilson disease. J. Biol. Chem. 282: 8343-8355.
43. Ralle, M. et al. 2010. Wilson disease at a single cell level: intracellular copper trafficking activates compartment-specific responses in hepatocytes. J. Biol. Chem. 285: 30875-30883.
44. Levy, E. et al. 2007. Abnormal hepatobiliary and circulating lipid metabolism in the Long-Evans Cinnamon rat model of Wilson's disease. Life Sci. 80: 1472-83.
45. Serviddio, G., F. Bellanti & G. Vendemiale. 2013. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic. Biol. Med. 65C: 952-968.
46. He, K. et al. 2011. Identification of high-copper-responsive target pathways in Atp7b knockout mouse liver by GSEA on microarray data sets. Mamm. Genome. 22: 703-713.
47. Burkhead, J. L., L. W. Gray & S. Lutsenko. 2011. Systems biology approach to Wilson's disease. Biometals. 24: 455-466.
48. Nagasaka, H. et al. 2012. Fatty liver and anti-oxidant enzyme activities along with peroxisome proliferator-activated receptors gamma and alpha expressions in the liver of Wilson's disease. Mol. Genet. Metab. 107: 542-547.
49. Rodo, M. et al. 2000. The level of serum lipids, vitamin E and low density lipoprotein oxidation in Wilson's disease patients. Eur. J. Neurol. 7: 491-494.
50. Seessle, J. et al. 2011. Alterations of lipid metabolism in Wilson disease. Lipids Health Dis. 10: 83.
51. Walshe, J. M. 1996. Treatment of Wilson's disease: the historical background. QJM. 89: 553-555.